KR101522924B1 - 1-(치환된 페닐)-5-트리플루오로메틸-2-(1ｈ)피리돈 화합물 및 이것의 염의 제조방법 및 용도 - Google Patents

1-(치환된 페닐)-5-트리플루오로메틸-2-(1ｈ)피리돈 화합물 및 이것의 염의 제조방법 및 용도 Download PDF

Info

Publication number
KR101522924B1
KR101522924B1 KR1020117030518A KR20117030518A KR101522924B1 KR 101522924 B1 KR101522924 B1 KR 101522924B1 KR 1020117030518 A KR1020117030518 A KR 1020117030518A KR 20117030518 A KR20117030518 A KR 20117030518A KR 101522924 B1 KR101522924 B1 KR 101522924B1
Authority
KR
South Korea
Prior art keywords
trifluoromethyl
pyridone
compound
group
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117030518A
Other languages
English (en)
Korean (ko)
Other versions
KR20120025541A (ko
Inventor
가오윤 후
리지안 타오
준 첸
Original Assignee
센트럴 사우스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센트럴 사우스 유니버시티 filed Critical 센트럴 사우스 유니버시티
Publication of KR20120025541A publication Critical patent/KR20120025541A/ko
Application granted granted Critical
Publication of KR101522924B1 publication Critical patent/KR101522924B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020117030518A 2009-05-25 2010-05-24 1-(치환된 페닐)-5-트리플루오로메틸-2-(1ｈ)피리돈 화합물 및 이것의 염의 제조방법 및 용도 Expired - Fee Related KR101522924B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200910043501 2009-05-25
CN200910043501.7 2009-05-25
PCT/CN2010/073105 WO2010135972A1 (zh) 2009-05-25 2010-05-24 1-(取代芳基)-5-三氟甲基-2-（1h）吡啶酮化合物及其盐的制备方法及其用途

Publications (2)

Publication Number Publication Date
KR20120025541A KR20120025541A (ko) 2012-03-15
KR101522924B1 true KR101522924B1 (ko) 2015-05-26

Family

ID=43222160

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117030518A Expired - Fee Related KR101522924B1 (ko) 2009-05-25 2010-05-24 1-(치환된 페닐)-5-트리플루오로메틸-2-(1ｈ)피리돈 화합물 및 이것의 염의 제조방법 및 용도

Country Status (7)

Country Link
US (1) US8426407B2 (enExample)
EP (1) EP2436670B1 (enExample)
JP (1) JP5583758B2 (enExample)
KR (1) KR101522924B1 (enExample)
CN (1) CN102149682B (enExample)
AU (1) AU2010252447B2 (enExample)
WO (1) WO2010135972A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5587184B2 (ja) 2007-06-20 2014-09-10 オースペックス・ファーマシューティカルズ・インコーポレイテッド 繊維症阻害剤としての置換ｎ−アリールピリジノン
US9434695B2 (en) 2012-07-18 2016-09-06 Sunshine Lake Pharma Co., Ltd Nitrogenous heterocyclic derivatives and their application in drugs
CN102786467A (zh) * 2012-08-15 2012-11-21 浙江省医学科学院 一种n-取代芳基吡啶酮化合物及其制备方法和应用
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9902712B2 (en) 2013-12-19 2018-02-27 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
WO2015171345A1 (en) * 2014-04-30 2015-11-12 Auspex Pharmaceuticals, Inc. N-aryl pyridinones modulators of fibrosis and/or collagen infiltration
CN106466318B (zh) * 2015-08-21 2019-01-01 中南大学 1-杂环取代苄基吡啶酮类化合物在制备治疗糖尿病肾病药物中的应用
CN113476447A (zh) * 2021-07-09 2021-10-08 中南大学 一种美氟尼酮在制备急性肝损伤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080023680A (ko) * 2005-05-10 2008-03-14 인터뮨, 인크. 스트레스-활성화 단백질 키나제 시스템을 조절하기 위한피리돈 유도체

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
GB8523126D0 (en) 1985-09-19 1985-10-23 Ici Plc Aryl pyridones
GB8621217D0 (en) 1986-09-03 1986-10-08 Ici Plc Chemical compounds
GB8825314D0 (en) 1988-10-28 1988-11-30 Ici Plc Chemical compounds
GB9006479D0 (en) 1989-04-17 1990-05-23 Ici Plc Novel compounds
US5716632A (en) 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5518729A (en) 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5238906A (en) 1990-11-27 1993-08-24 Sumitomo Chemical Company, Limited Pyridone derivatives and use
DE4343528A1 (de) 1993-12-16 1995-06-22 Schering Ag Zweifach heterocyclisch substituierte Benzole und Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
SI1490064T1 (sl) 2002-02-14 2010-01-29 Pharmacia Corp Substituirani piridinoni kot modulatorji p38 MAP kinaze
CN1218942C (zh) * 2002-06-11 2005-09-14 中南大学湘雅医学院 抗纤维化吡啶酮化合物及其生产工艺方法
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
CA2545813C (en) 2003-11-14 2011-01-04 Shanghai Genomics, Inc. The derivatives of pyridone and use thereof
DE102004027359A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
ZA200709593B (en) 2005-05-10 2009-06-24 Intermune Inc Pyridone derivatives for modulating stress-activated protein kinase system
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
EP1960405A2 (en) 2005-11-23 2008-08-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
CN101235030A (zh) * 2007-01-30 2008-08-06 中南大学 1-取代-5-三氟甲基-2-(1h)吡啶酮化合物、制备方法及其用途
WO2008154207A1 (en) 2007-06-08 2008-12-18 The Burnham Institute For Medical Research Methods and compounds for regulating apoptosis
CN101371833A (zh) 2007-08-23 2009-02-25 中南大学 1-芳基-2(1h)-吡啶酮类化合物在制备治疗皮肤瘙痒药物中的应用
JP5627574B2 (ja) * 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
US20100190731A1 (en) 2009-01-26 2010-07-29 Jeff Olgin Methods for treating acute myocardial infarctions and associated disorders
WO2010135470A1 (en) 2009-05-19 2010-11-25 Intermune, Inc. Pifenidone derivatives for treating bronchial asthma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080023680A (ko) * 2005-05-10 2008-03-14 인터뮨, 인크. 스트레스-활성화 단백질 키나제 시스템을 조절하기 위한피리돈 유도체

Also Published As

Publication number Publication date
EP2436670B1 (en) 2014-04-16
AU2010252447B2 (en) 2014-08-28
US8426407B2 (en) 2013-04-23
CN102149682B (zh) 2012-12-05
CN102149682A (zh) 2011-08-10
JP2012527487A (ja) 2012-11-08
KR20120025541A (ko) 2012-03-15
EP2436670A1 (en) 2012-04-04
AU2010252447A1 (en) 2011-12-15
US20120142688A1 (en) 2012-06-07
EP2436670A4 (en) 2012-11-21
JP5583758B2 (ja) 2014-09-03
WO2010135972A1 (zh) 2010-12-02
HK1164297A1 (en) 2012-10-12

Similar Documents

Publication Publication Date Title
KR101522924B1 (ko) 1-(치환된 페닐)-5-트리플루오로메틸-2-(1ｈ)피리돈 화합물 및 이것의 염의 제조방법 및 용도
KR101478133B1 (ko) 1-（치환된 벤질기）-5-트리플루오로메틸-2-（1ｈ）피리돈 화합물 및 그 염의 제조방법 및 용도
CN102391287B (zh) 左旋氟喹诺酮c3双唑甲硫醚、制备方法及其应用
CN108530310B (zh) 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用
JP2020510642A (ja) ｏ−アミノヘテロアリールアルキニル基含有化合物およびその製造方法と用途
Moghimi et al. Design and synthesis of novel pyridazine N-aryl acetamides: In-vitro evaluation of α-glucosidase inhibition, docking, and kinetic studies
IL170093A (en) Method for preparing acid addition salts of polyacidic basic compounds
KR20240154590A (ko) Lpa 수용체 활성과 연관된 상태를 치료하기 위한 화합물 및 조성물
CN117769556A (zh) 嘧啶并环类衍生物及其制备方法和用途
CN110256405B (zh) 5-烃基-n-取代芳基吡啶酮衍生物及其制备方法和用途
JP5969604B2 (ja) ピペラジン誘導体、それらの製造方法及びインスリン抵抗性の処置におけるそれらの使用
CN101759665B (zh) 取代苯基哌嗪芳烷醇衍生物及其在制备镇痛药物中的应用
HK1164297B (en) Preparation of 1-(substituted aryl)-5-trifluoromethyl-2-(1h)-pyridone compounds and salts thereof and their applications
MXPA05002331A (es) Inhibidores de productos terminales de glicacion avanzada post-amadori.
HK1166791B (en) Preparation of 1-(substituted benzyl)-5-trifluoromethyl-2-(1h)pyridone compounds and salts thereof and their applications
CN104311452B (zh) 腈基萘环的丁二酸酰胺衍生物、其制备方法及用途
CN104311441B (zh) 一类氯代萘环的丁二酸酰胺衍生物、其制备方法及用途
CN120923388A (zh) 芳香磺胺类化合物及其制备方法和应用
CN104292124B (zh) 硝基苯基取代的萘环丁二酸酰胺衍生物、其制备方法及用途
CN113999250A (zh) 一种以氧氟沙星为原料制备的异白叶藤碱类似物及其制备方法和应用
TR2024002067A2 (tr) Anti̇-kanser özelli̇ği̇ne sahi̇p ki̇nolon kalkon türevleri̇ ve farmasöti̇k kompozi̇syonlari
CN104311443B (zh) 一类含萘环的丁二酸酰胺衍生物、其制备方法及用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180520

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180520